Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations. These therapies aim to serve broad genetically defined patient populations, overcome resistance, reduce wild-type toxicities, and penetrate the brain for central nervous system (CNS) diseases. They are advancing two programs: BDTX-1535, an EGFR MasterKey inhibitor for EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a RAF MasterKey inhibitor for KRAS, NRAS, and BRAF alterations in solid tumors. They also have BDTX-4876, targeting FGFR2/3 mutations, and another candidate targeting an undisclosed oncogene. The BDTX average annual return since 2020 is shown above.
The Average Annual Return on the BDTX average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BDTX average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BDTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|